Skip to main content
Premium Trial:

Request an Annual Quote

TGen, Flagship Partner to Hasten Drug Development

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – TGen Drug Development and Flagship Biosciences today announced a partnership to use their technologies to hasten new drug development.

The deal combines TGen's molecular analysis tools with Flagship's expertise in high-throughput immunohistochemistry to support preclinical drug development and human clinical trials.

Financial and other terms of the deal were not disclosed.

Based in Flagstaff, Ariz., Flagship provides computerized histopathology and expertise in measuring epithelial-mesenchymal transition, when tumor cells become invasive, migratory, and drug resistant.

"Flagship's technology will significantly accelerate our ability to identify biomarkers that could help researchers predict which drug compounds will work best on specific patient cancers," Stephen Gately, president of Scottsdale, Ariz.-based TGen Drug Development, said in a statement.

TGen Drug Development is a non-profit subsidiary of Phoenix-based Translational Genomics Research Institute.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.